|Mr. Andrew P. Rasdal||CEO, Pres & Director||325.99k||N/A||1958|
|Mr. Mark C. Brister||Chief Technology Officer||403.49k||N/A||1962|
|Ms. Amy VandenBerg||Chief Quality Assurance, Clinical & Regulatory Affairs Officer||403.49k||N/A||1975|
|Dr. Kelly Huang Ph.D.||Consultant||479.82k||N/A||1969|
|Ms. Nooshin Hussainy||Chief Financial Officer||N/A||N/A||1958|
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Obalon Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.